ENTL Entelos Regs

    


Entelos Inc.



                                  ENTELOS, INC.

         NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2008

                         Results Date: 23 September 2008

Entelos, Inc. (LSE: ENTL), a leading life sciences company applying predictive
technologies and "virtual humans" to accelerate drug development and improve the
quality of health-related products, announces that it will be releasing its
interim results for the six months ended 30 June 2008 on Tuesday 23 September
2008.

Analyst Briefing:

An Analyst briefing will be held at 10:00 am on 23 September at the offices of
Buchanan Communications, 45 Moorfields, London, EC2.

For further information please contact:

Entelos, Inc.
James Karis, President and CEO                              Tel: +1-650-572-5400
Jill Fujisaki, Vice President, Investor
 Relations
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson                         Tel +44-0-20-7466-5000

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual human" technology, and toxicology reference
systems to develop safer and more effective drugs, improve the quality of
health-related consumer products, and deliver on the promise of personalized
medicine. Entelos provides customized products, technology and research services
to global pharmaceutical, health-care, and consumer products companies in safety
testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes,
hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal
care products.

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024